Thane: Two COVID-19 patients have died due to mucormycosis, a serious but rare fungal infection, in Maharashtra’s Thane district, a health official said on Wednesday.
Besides, six other patients are currently undergoing treatment for the disease, also known as black fungus, the official said.
A 38-year-old patient from Mharal in Thane rural and another one from Dombivli town died of the fungal infection while undergoing treatment at different COVID-19 care centres in Kalyan Dombivli Municipal Corporation (KDMC) limits, the civic body’s health officer Dr Ashwini Patil said.
Six other patients were undergoing treatment for mucormycosis and two of them were admitted in the ICUs, she said.
The official also said COVID-19 patients need not panic as this fungal infection is mostly being found in those having diabetes. Such patients need to keep their blood sugar level under control, she said.
Mucormycosis is being detected in COVID-19 patients and there should not be an excessive use of steroids for their treatment, the official said.
According to health experts, the symptoms of mucormycosis include headache, fever, pain under the eyes, nasal or sinus congestion and partial loss of vision.
On Tuesday, Maharashtra Health Minister Rajesh Tope said there could be over 2,000 mucormycosis patients in the state as of now and with more and more COVID-19 cases coming up, “their number would increase for sure”.
The state government has decided to use hospitals attached to medical colleges as treatment centres for mucormycosis, he had said.
Meanwhile, Lok Sabha member from Kalyan Dr Shrikant Shinde in a release said during a virtual meeting with Chief Minister Uddhav Thackeray over the weekend, he made several suggestions on how to tackle the fungal infection.
Shinde also suggested that a task force be set up to lay down protocols for the use of steroids for treating COVID-19 patients.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .